KR102610645B1 - A rapid preparation method for a peracetic acid solution provided as single formulation - Google Patents
A rapid preparation method for a peracetic acid solution provided as single formulation Download PDFInfo
- Publication number
- KR102610645B1 KR102610645B1 KR1020210142044A KR20210142044A KR102610645B1 KR 102610645 B1 KR102610645 B1 KR 102610645B1 KR 1020210142044 A KR1020210142044 A KR 1020210142044A KR 20210142044 A KR20210142044 A KR 20210142044A KR 102610645 B1 KR102610645 B1 KR 102610645B1
- Authority
- KR
- South Korea
- Prior art keywords
- peracetic acid
- acid solution
- weight
- acid
- present
- Prior art date
Links
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 title claims abstract description 160
- 239000000203 mixture Substances 0.000 title claims description 37
- 238000002360 preparation method Methods 0.000 title claims description 13
- 238000009472 formulation Methods 0.000 title description 16
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 50
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims abstract description 45
- 238000004519 manufacturing process Methods 0.000 claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000004327 boric acid Substances 0.000 claims abstract description 28
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- 239000003381 stabilizer Substances 0.000 claims abstract description 15
- 238000002156 mixing Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 230000032683 aging Effects 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 13
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 5
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 16
- 239000008213 purified water Substances 0.000 abstract description 15
- 150000003839 salts Chemical class 0.000 abstract description 11
- 239000000645 desinfectant Substances 0.000 abstract description 10
- 239000003054 catalyst Substances 0.000 abstract description 8
- 238000011109 contamination Methods 0.000 abstract description 3
- 239000013049 sediment Substances 0.000 abstract description 3
- 239000003085 diluting agent Substances 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 39
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 34
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 101100376153 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TY2A-F gene Proteins 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 238000001223 reverse osmosis Methods 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 239000008399 tap water Substances 0.000 description 6
- 235000020679 tap water Nutrition 0.000 description 6
- 239000003377 acid catalyst Substances 0.000 description 5
- 238000013094 purity test Methods 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000010198 maturation time Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 229940079920 digestives acid preparations Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000034809 Product contamination Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical class [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group; Thio analogues thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
Landscapes
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Toxicology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
본 발명은 과아세트산 용액의 신속 제조방법에 관한 것으로, 구체적으로 아세트산 무수물, 과산화수소, 물, 안정화제 및 붕산을 단시간 반응시키는 단계를 포함하는 과아세트산 용액의 제조방법, 및 이로부터 제조된 과아세트산 용액에 관한 것이다.
본 발명의 과아세트산 용액의 제조방법은 종래 제조방법에 비해 제조시간을 현저히 단축시킬 수 있고, 제조 공정이 간편하고 제조 비용이 저렴하다. 뿐만 아니라 1 제, 2 제를 혼합하고 다시 정제수로 희석하여 사용하는 기존 제품과 달리, 본 발명의 과아세트산 용액은 단일제로서 유통이 편리하고, 1 제에 정제수를 희석하여 바로 사용이 가능한 편리성을 제공하며, 장기 보존시에도 침전물의 발생이 없고 실용액 제조에 따른 오염의 위험성이 적어 의료기기의 소독살균제로서 매우 유용하게 사용될 수 있다. 또한, 촉매로 붕산을 사용함으로써 염 형성 문제가 적어 소독살균제로서 이용에 매우 편리하다.The present invention relates to a rapid method for producing a peracetic acid solution, and specifically, to a method for producing a peracetic acid solution comprising the step of reacting acetic anhydride, hydrogen peroxide, water, a stabilizer, and boric acid for a short time, and a peracetic acid solution prepared therefrom. It's about.
The method for producing a peracetic acid solution of the present invention can significantly shorten the production time compared to the conventional production method, the production process is simple, and the production cost is low. In addition, unlike existing products that mix agent 1 and agent 2 and then dilute them with purified water, the peracetic acid solution of the present invention is convenient to distribute as a single agent and can be used immediately by diluting agent 1 with purified water. It can be very useful as a disinfectant for medical devices, as it does not produce sediment even during long-term storage and has a low risk of contamination due to the production of practical solutions. In addition, by using boric acid as a catalyst, there is less salt formation problem, making it very convenient to use as a disinfectant.
Description
본 발명은 과아세트산 용액의 신속 제조방법에 관한 것으로, 구체적으로 아세트산 무수물, 과산화수소, 물, 안정화제 및 붕산을 단시간 반응시키는 단계를 포함하는 과아세트산 용액의 제조방법, 및 이로부터 제조된 과아세트산 용액에 관한 것이다.The present invention relates to a rapid method for producing a peracetic acid solution, and specifically, to a method for producing a peracetic acid solution comprising the step of reacting acetic anhydride, hydrogen peroxide, water, a stabilizer, and boric acid for a short time, and a peracetic acid solution prepared therefrom. It's about.
최근 노령 인구와 만성질환자 증가, 항암제 및 면역억제제 사용으로 인한 면역부전환자의 증가 등으로 침습적 의료 행위에 이용되는 의료기구의 살균/소독이 매우 중요하게 다루어지고 있다. 의료기구의 살균/소독이 제대로 되지 못할 경우 병원균 감염으로 인해 환자의 건강을 위협할 수 있으며, 이로 인해 입원 기간 연장, 의료비용 증가 등으로 사회적 손실이 발생할 수 있다. 현재 국내에서 의료기구의 살균소독제로 시판 중인 제품의 성분은 과아세트산, 산화에틸렌, 시트르산수화물, 염화벤잘코늄, 클로르헥시딘글루콘산염 등으로 다양하다.Recently, the sterilization/disinfection of medical instruments used in invasive medical procedures has become very important due to the increase in the aging population, the increase in patients with chronic diseases, and the increase in immunocompromised patients due to the use of anticancer drugs and immunosuppressants. If the sterilization/disinfection of medical equipment is not done properly, the patient's health may be threatened due to pathogen infection, which may lead to social losses due to prolonged hospitalization and increased medical costs. The ingredients of products currently sold as disinfectants for medical devices in Korea are diverse, including peracetic acid, ethylene oxide, citric acid hydrate, benzalkonium chloride, and chlorhexidine gluconate.
이 중 과아세트산 용액은 과아세트산을 함유하는 평형 용액을 말하며, 일반 세균뿐만 아니라 각종 진균, 항산성균, 포자에 대한 살균 효과를 가지고, 또한 단순포진 바이러스, 아데노바이러스, 소아마비 바이러스 등을 불활성화하는 것으로 알려져 있다. 따라서 과아세트산 용액은 의료기구의 살균소독 용도로 매우 유용하게 사용되고 있다. Among these, peracetic acid solution refers to a balanced solution containing peracetic acid, and has a sterilizing effect not only on general bacteria but also on various fungi, acid-fast bacteria, and spores, and is also known to inactivate herpes simplex virus, adenovirus, and polio virus. there is. Therefore, peracetic acid solution is very useful for sterilizing and disinfecting medical instruments.
대한민국 등록특허 제10-0426937호는 과아세트산 용액의 실용액이 적어도 7 일간 유지되는 조성물을 개시하고 있는데, 종래 제제의 실용액 (과아세트산 약 2 % 함유)의 셀프 라이프가 1 일 내지 3 일 수준인 점을 개선하기 위해 과아세트산을 함유하는 제1 시약과 인산염 및 비이온 계면활성제를 함유하는 제2 시약을 별도로 제조하고, 사용 시 상기 제1 시약과 제2 시약을 혼합하여 사용하는 형태의 과아세트산 용액을 개시하고 있다. 또한, 대한민국 등록특허 제10-0876684호는 과아세트산 및 아세틸살리실산을 함유하는 살균 조성물을 개시하고 있는데, 초산, 과산화수소, 과초산을 함유하는 제1 용액 및 아세틸살리실산을 함유하는 제2 용액을 혼합하여 사용하는 형태로서, 정제수로 희석될 경우에도 3 주 이상 장시간 보존하며 사용될 수 있음을 개시하고 있다. 그러나 이와 같이 살균 조성물을 2 종의 용액으로 구성하여 제공할 경우, 제조 공정이 매우 복잡해지고 제조 비용이 증가할 뿐만 아니라, 실용액 제조 시 두 용액을 혼합하는 과정을 반드시 거쳐야하므로 사용이 불편하며, 혼합 과정에서 제품이 오염될 위험도가 증가하여 위생 상 불리하다는 단점을 가진다.Republic of Korea Patent No. 10-0426937 discloses a composition in which the practical solution of peracetic acid solution is maintained for at least 7 days, and the self-life of the practical solution (containing about 2% of peracetic acid) of a conventional preparation is 1 to 3 days. In order to improve this point, a first reagent containing peracetic acid and a second reagent containing phosphate and a non-ionic surfactant are prepared separately, and the first reagent and the second reagent are mixed when used. Acetic acid solution is disclosed. In addition, Republic of Korea Patent No. 10-0876684 discloses a sterilizing composition containing peracetic acid and acetylsalicylic acid, which is obtained by mixing a first solution containing acetic acid, hydrogen peroxide, and peracetic acid and a second solution containing acetylsalicylic acid. As a form of use, it is disclosed that even when diluted with purified water, it can be stored and used for a long time, more than 3 weeks. However, when the sterilizing composition is provided as a composition of two types of solutions, not only does the manufacturing process become very complicated and the manufacturing cost increase, but it is also inconvenient to use because the process of mixing the two solutions must be performed when preparing the practical solution. It has the disadvantage of being hygienic as the risk of product contamination increases during the mixing process.
한편, 종래 단일제 형태로 제공되는 살균 조성물로서 대한민국 등록특허 제10-0363896호에서는 과초산, 인산 등을 포함하는 의료기기 세척제를 개시하고, 대한민국 등록특허 제10-0597092호에서는 과초산, 유기산 (시트릭산, 말릭산, 글리콜릭산, 옥살산, 숙신산, 포름산) 등을 포함하는 과초산 수용액을 개시하고 있으나, 이들 모두 반응 후 최소 3 일 내지 10 일 간의 숙성 시간을 필요로 하여 제조 시간이 오래 걸린다는 한계가 있었다. 또한, 종래 살균 조성물은 좋은 품질의 정제수, 역삼투압수 등의 특정 용매와 혼합하여 사용하지 않을 경우 염을 형성하는 문제가 있어 사용에 불편함이 있었다.Meanwhile, as a conventional sterilizing composition provided in the form of a single agent, Republic of Korea Patent No. 10-0363896 discloses a medical device cleaner containing peracetic acid and phosphoric acid, and Republic of Korea Patent No. 10-0597092 discloses peracetic acid and organic acid (sheet) An aqueous solution of peracetic acid containing (lic acid, malic acid, glycolic acid, oxalic acid, succinic acid, formic acid), etc. is disclosed, but all of them require a maturation time of at least 3 to 10 days after reaction, so the manufacturing time is long. There was. In addition, conventional sterilizing compositions have the problem of forming salts if they are not mixed with a specific solvent such as good quality purified water or reverse osmosis water, causing inconvenience in use.
본 발명의 하나의 목적은, (a) 아세트산 무수물 37 중량% 내지 41 중량%, 과산화수소 10 중량% 내지 12 중량% 및 물을 혼합하는 단계; (b) 상기 (a) 단계의 혼합물에 안정화제를 첨가하여 혼합하는 단계; 및 (c) 상기 (b) 단계의 혼합물에 붕산 0.5 중량% 내지 5 중량%를 혼합하고 30 ℃ 내지 50 ℃에서 2 시간 내지 4 시간 동안 반응시키는 단계를 포함하는, 단일제로 제공되는 과아세트산 용액의 제조방법을 제공하는 것이다.One object of the present invention is to (a) mix 37% to 41% by weight of acetic anhydride, 10% to 12% by weight of hydrogen peroxide, and water; (b) adding and mixing a stabilizer to the mixture of step (a); and (c) mixing 0.5% by weight to 5% by weight of boric acid with the mixture of step (b) and reacting at 30°C to 50°C for 2 to 4 hours. It provides a manufacturing method.
본 발명의 다른 하나의 목적은, 상기 제조방법으로 제조된 과아세트산 용액을 단일제 형태로 제공하는 것이다.Another object of the present invention is to provide the peracetic acid solution prepared by the above production method in the form of a single agent.
이를 구체적으로 설명하면 다음과 같다. 한편, 본 발명에서 개시된 각각의 설명 및 실시형태는 각각의 다른 설명 및 실시 형태에도 적용될 수 있다. 즉, 본 발명에서 개시된 다양한 요소들의 모든 조합이 본 발명의 범주에 속한다. 또한, 하기 기술된 구체적인 서술에 의하여 본 발명의 범주가 제한된다고 볼 수 없다.This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in the present invention may also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Additionally, the scope of the present invention cannot be considered limited by the specific description described below.
상기 목적을 달성하기 위한 본 발명의 하나의 양태는, (a) 아세트산 무수물 37 중량% 내지 41 중량%, 과산화수소 10 중량% 내지 12 중량% 및 물을 혼합하는 단계; (b) 상기 (a) 단계의 혼합물에 안정화제를 첨가하여 혼합하는 단계; 및 (c) 상기 (b) 단계의 혼합물에 붕산 0.5 중량% 내지 5 중량%를 혼합하고 30 ℃ 내지 50 ℃에서 2 시간 내지 4 시간 동안 반응시키는 단계를 포함하는, 단일제로 제공되는 과아세트산 용액의 제조방법이다.One aspect of the present invention for achieving the above object is the step of (a) mixing 37% to 41% by weight of acetic anhydride, 10% to 12% by weight of hydrogen peroxide, and water; (b) adding and mixing a stabilizer to the mixture of step (a); and (c) mixing 0.5% by weight to 5% by weight of boric acid with the mixture of step (b) and reacting at 30°C to 50°C for 2 to 4 hours. It is a manufacturing method.
본 발명에서 용어 "과아세트산 용액 (peracetic acid solution)"은 과아세트산을 포함하는 용액을 지칭하며, 과초산 용액과 같은 의미로 사용된다. 과아세트산 용액은 세균, 진균, 박테리아 등에 항균활성을 가지므로 의료기구의 소독세정제로서 매우 유용하게 사용될 수 있다. 특히, 본 발명의 제조방법에 의해 제조된 과아세트산 용액은 종래 기술과 달리 단일제로 제공되어 제조 공정이 간편하고 제조 비용이 저렴하며, 유통이 편리하고, 사용이 용이하며, 실용액 제조에 따른 오염의 위험성이 상대적으로 적다. In the present invention, the term “peracetic acid solution” refers to a solution containing peracetic acid and is used in the same sense as peracetic acid solution. Peracetic acid solution has antibacterial activity against germs, fungi, bacteria, etc., so it can be very useful as a disinfectant and cleaner for medical devices. In particular, the peracetic acid solution prepared by the manufacturing method of the present invention is provided as a single agent, unlike the prior art, so the manufacturing process is simple, the manufacturing cost is low, distribution is convenient, and it is easy to use, and is free from contamination caused by manufacturing the practical solution. The risk is relatively small.
상기 제조방법에서 (a) 단계는 아세트산 무수물 37 중량% 내지 41 중량%, 과산화수소 10 중량% 내지 12 중량% 및 물을 혼합하는 단계이다. 통상 과아세트산을 제조하기 위해 아세트산 (CH3COOH)과 과산화수소 (H2O2)를 반응시키는데, 본 발명에서 출발물질로 채택한 아세트산 무수물 ((CH3CO)2O)은 생성물에서 아세트산 대비 수분 함량이 상대적으로 낮다는 점에서 차이를 갖는다. 본 발명에서는 구체적인 실험을 통하여 제조 시간을 단축시킬 수 있는 각 성분의 최적 함량 및 최적 공정을 도출하였다. In the above manufacturing method, step (a) is a step of mixing 37% to 41% by weight of acetic anhydride, 10% to 12% by weight of hydrogen peroxide, and water. Typically, acetic acid (CH 3 COOH) and hydrogen peroxide (H 2 O 2 ) are reacted to produce peracetic acid, and acetic anhydride ((CH 3 CO) 2 O) used as a starting material in the present invention has a water content compared to acetic acid in the product. The difference is that it is relatively low. In the present invention, through specific experiments, the optimal content and optimal process of each ingredient that can shorten the manufacturing time were derived.
본 발명에서 물은 정제수, 역삼투압수 또는 일반 수돗물일 수 있으나, 이에 제한되지 않는다. 후술하는 바와 같이, 본 발명의 과아세트산 용액은 염 형성 문제가 적어 사용상 편리성을 갖는다.In the present invention, water may be purified water, reverse osmosis water, or general tap water, but is not limited thereto. As will be described later, the peracetic acid solution of the present invention has little salt formation problem and is convenient for use.
단계 (b)는 상기 (a) 단계의 혼합물에 안정화제를 첨가하여 혼합하는 단계이다. 상기 안정화제는 1-히드록시에탄-1,1-디포스폰산, 1-옥탄설폰산나트륨, {[(카르복시메틸)이미노]비스(에틸렌니트릴로)}테트라아세트산, EDTA 소듐염 또는 이들의 조합일 수 있으나 이에 제한되는 것은 아니다. 과아세트산 수용액은 평형 상태로 존재하므로 본 발명에서 안정화제는 과아세트산 용액의 평형 상태를 안정화시킬 수 있는 임의의 물질을 적절히 선택하여 사용할 수 있다. 상기 안정화제의 함량은 과아세트산 용액의 안정성, 부식성 등을 고려하여 적절히 조절될 수 있으며, 예컨대 0.1 중량% 내지 3 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다. Step (b) is a step of adding and mixing a stabilizer to the mixture of step (a). The stabilizer is 1-hydroxyethane-1,1-diphosphonic acid, sodium 1-octanesulfonate, {[(carboxymethyl)imino]bis(ethylenenitrilo)}tetraacetic acid, EDTA sodium salt, or sodium salt thereof. It may be a combination, but is not limited thereto. Since the aqueous peracetic acid solution exists in an equilibrium state, in the present invention, any material capable of stabilizing the equilibrium state of the peracetic acid solution can be appropriately selected and used as the stabilizer. The content of the stabilizer may be appropriately adjusted in consideration of the stability and corrosiveness of the peracetic acid solution, and may be included at, for example, 0.1% by weight to 3% by weight, but is not limited thereto.
단계 (c)는 상기 (b) 단계의 혼합물에 붕산 0.5 중량% 내지 5 중량%를 혼합하고 30 ℃ 내지 50 ℃에서 2 시간 내지 4 시간 동안 반응시키는 단계이다. Step (c) is a step of mixing 0.5% by weight to 5% by weight of boric acid with the mixture of step (b) and reacting at 30°C to 50°C for 2 to 4 hours.
본 발명의 제조방법은 특히 과아세트산의 평형반응을 촉진시키기 위한 산 촉매로 붕산을 채택한 것을 기술적 특징으로 한다. 종래 인산, 황산, 또는 시트릭산, 글리콜릭산, 옥살산, 숙신산, 포름산과 같은 유기산을 산 촉매로 사용하여 과아세트산 수용액을 제조하는 방법은 공지된 바 있으나, 본 발명과 같이 붕산을 사용한 예는 전혀 알려진 바 없다. The production method of the present invention is particularly characterized by the adoption of boric acid as an acid catalyst to promote the equilibrium reaction of peracetic acid. Conventionally, a method of preparing an aqueous peracetic acid solution using phosphoric acid, sulfuric acid, or organic acids such as citric acid, glycolic acid, oxalic acid, succinic acid, and formic acid as an acid catalyst is known, but there is no known example of using boric acid as in the present invention. There is no bar.
병원 및 의료기관에서 살균소독제로 과아세트산 제제를 사용할 경우, 일반적으로 정제수 또는 역삼투압수를 사용하지만, 편의상 혹은 비용상의 문제로 좋은 품질의 정제수, 역삼투압수 등을 사용하지 않고 수돗물, 또는 기준에 미달하는 정제수, 역삼투압수 등에 희석하여 사용하는 경우가 빈번히 발생한다. 이와 같이 과아세트산 제제 (기존 제제의 경우, 인산을 함유하는 제형이 다수)를 수돗물 등에 희석하여 사용할 경우, 염을 형성하여 침전물이 형성되고 소독기 장비에 펌프, 파이프, 용매 흐름관에 염이 침적되는 문제가 많이 지적되어왔다. 그러나 붕산을 사용한 본 발명의 과아세트산 용액은 이러한 문제점을 전혀 나타내지 않는다. When hospitals and medical institutions use peracetic acid as a disinfectant, they generally use purified water or reverse osmosis water. However, for convenience or cost reasons, they do not use good quality purified water or reverse osmosis water, but use tap water or water that does not meet the standards. It is frequently used by diluting it with purified water, reverse osmosis water, etc. In this way, when peracetic acid preparations (in the case of existing preparations, many formulations containing phosphoric acid) are used by diluting them with tap water, salts are formed and precipitates are formed, and salts are deposited on pumps, pipes, and solvent flow pipes in the sterilizer equipment. Many problems have been pointed out. However, the peracetic acid solution of the present invention using boric acid does not exhibit any of these problems.
구체적으로 상기 단계 (c)는 35 ℃ 내지 45 ℃에서 3 시간 동안 반응시키는 것일 수 있으나, 이에 제한되는 것은 아니다. 상기 명시된 온도, 시간 조건에서 다소 차이가 나더라도 본 발명과 동등한 제조 시간 단축 효과를 나타내는 한 모두 균등 범위로서 본 발명의 범주에 포함될 수 있음은 당업자에게 자명하다.Specifically, step (c) may involve reacting at 35°C to 45°C for 3 hours, but is not limited thereto. It is obvious to those skilled in the art that even if there are some differences in the temperature and time conditions specified above, they can all be included in the scope of the present invention as equivalent ranges as long as they exhibit the same manufacturing time reduction effect as the present invention.
한편, 이에 제한되는 것은 아니나 본 발명의 일 실시양태로서, 상기 (a) 단계의 아세트산 무수물은 39 중량%이고, 과산화수소수는 11.5 중량%이며, 상기 (c) 단계의 붕산은 2 중량%이고, 30 ℃ 내지 40 ℃에서 반응시키는 것일 수 있다.Meanwhile, as an embodiment of the present invention, but not limited thereto, the acetic anhydride in step (a) is 39% by weight, the hydrogen peroxide solution is 11.5% by weight, and the boric acid in step (c) is 2% by weight, The reaction may be carried out at 30°C to 40°C.
본 발명의 다른 일 실시양태로서, 상기 (a) 단계의 아세트산 무수물은 37 중량% 내지 41 중량%이고, 과산화수소수는 11.5 중량%이며, 상기 (c) 단계의 붕산은 2 중량%이고, 40 ℃ 내지 50 ℃에서 반응시키는 것일 수 있다.In another embodiment of the present invention, the acetic anhydride in step (a) is 37% to 41% by weight, the hydrogen peroxide is 11.5% by weight, the boric acid in step (c) is 2% by weight, and the temperature is 40°C. The reaction may be carried out at from 50°C.
본 발명의 제조방법은 추가적으로, (d) 상기 (c) 단계의 반응물을 상온에서 숙성시키는 단계를 포함하는 것일 수 있다. 상기 숙성시키는 단계는 바람직한 과아세트산 및 과산화수소 ?t량을 달성하기 위해 제조방법의 일 단계로서 포함될 수 있으며, 예컨대 1 시간 내지 3 시간일 수 있으나, 이에 제한되는 것은 아니다.The production method of the present invention may additionally include the step of (d) maturing the reactant of step (c) at room temperature. The aging step may be included as a step in the manufacturing method to achieve the desired amount of peracetic acid and hydrogen peroxide, for example, for 1 hour to 3 hours, but is not limited thereto.
본 발명의 구체적인 실시예에서는 산 촉매를 포함하지 않는 군 (기존 당사 제형, F005), 산 촉매로서 인산 (F002, F003) 또는 붕산 (F004, F006, F006-1, F007, F008)을 포함하는 군에 대하여 다양한 조건에서 실험을 수행하였다. 그 결과, 산 촉매로서 붕산을 채택할 경우 상온에서도 과초산 6 % 합성기간이 절반 수준으로 감소되는 것을 확인하였으며 (표 1, 도 1 및 도 2), 특히 온도를 35 ℃ 내지 45 ℃로 올려서 반응시킨 경우 최소 3 시간의 반응만으로 과초산 6 % 합성이 가능함을 확인하였다 (표 2, 표 3 및 도 3 내지 도 6). 따라서 본 발명의 제조방법은 매우 짧은 시간에 단일제로서 제공되는 과아세트산 용액을 제조할 수 있어, 종래 제조방법에 비해 현저히 우수한 제조 효율성을 갖는다. In specific examples of the present invention, a group containing no acid catalyst (our existing formulation, F005), a group containing phosphoric acid (F002, F003) or boric acid (F004, F006, F006-1, F007, F008) as an acid catalyst. Experiments were performed under various conditions. As a result, it was confirmed that when boric acid was used as the acid catalyst, the synthesis period of 6% peracetic acid was reduced by half even at room temperature (Table 1, Figures 1 and 2), and in particular, the reaction was carried out by raising the temperature to 35 ℃ to 45 ℃. It was confirmed that 6% peracetic acid could be synthesized with only a reaction of at least 3 hours (Table 2, Table 3 and Figures 3 to 6). Therefore, the production method of the present invention can produce a peracetic acid solution provided as a single agent in a very short time, and has significantly superior production efficiency compared to conventional production methods.
상기 목적을 달성하기 위한 본 발명의 다른 하나의 양태는 상기 제조방법으로 제조된, 단일제로 제공되는 과아세트산 용액이다. 상기 과아세트산 용액은 과아세트산을 5.4 중량% 내지 8 중량%로 함유하고 과산화수소를 10 중량% 이하로 함유하는 것일 수 있다. 본 발명의 과아세트산 용액은 상기 설명한 바와 같다.Another aspect of the present invention for achieving the above object is a peracetic acid solution prepared by the above production method and provided as a single agent. The peracetic acid solution may contain 5.4 to 8 wt% of peracetic acid and 10 wt% or less of hydrogen peroxide. The peracetic acid solution of the present invention is as described above.
본 발명의 과아세트산 용액은 내시경 등 의료기구의 세척 사용시 물에 희석하여 사용될 수 있다.The peracetic acid solution of the present invention can be diluted in water and used for cleaning medical instruments such as endoscopes.
본 발명의 과아세트산 용액의 제조방법은 종래 제조방법에 비해 제조시간을 현저히 단축시킬 수 있고, 제조 공정이 간편하고 제조 비용이 저렴하다. 뿐만 아니라 1 제, 2 제를 혼합하고 다시 정제수로 희석하여 사용하는 기존 제품과 달리, 본 발명의 과아세트산 용액은 단일제로서 유통이 편리하고, 1 제에 정제수를 희석하여 바로 사용이 가능한 편리성을 제공하며, 장기 보존시에도 침전물의 발생이 없고 실용액 제조에 따른 오염의 위험성이 적어 의료기기의 소독살균제로서 매우 유용하게 사용될 수 있다. 또한, 촉매로 붕산을 사용함으로써 염 형성 문제가 적어 소독살균제로서 이용에 매우 편리하다.The method for producing a peracetic acid solution of the present invention can significantly shorten the production time compared to the conventional production method, the production process is simple, and the production cost is low. In addition, unlike existing products that mix agent 1 and agent 2 and then dilute them with purified water, the peracetic acid solution of the present invention is convenient to distribute as a single agent and can be used immediately by diluting agent 1 with purified water. It can be very useful as a disinfectant for medical devices, as it does not produce sediment even during long-term storage and has a low risk of contamination due to the production of practical solutions. In addition, by using boric acid as a catalyst, there is less salt formation problem, making it very convenient to use as a disinfectant.
도 1은 상온에서 제조된 실시예 제제들의 과산화수소 함량을 숙성 시간에 따라 측정한 결과를 나타낸 것이다.
도 2는 상온에서 제조된 실시예 제제들의 과아세트산 함량을 숙성 시간에 따라 측정한 결과를 나타낸 것이다.
도 3은 35 ℃에서 제조된 실시예 제제들의 과산화수소 함량을 숙성 시간에 따라 측정한 결과를 나타낸 것이다.
도 4는 35 ℃에서 제조된 실시예 제제들의 과아세트산 함량을 숙성 시간에 따라 측정한 결과를 나타낸 것이다.
도 5는 45 ℃에서 제조된 실시예 제제들의 과산화수소 함량을 숙성 시간에 따라 측정한 결과를 나타낸 것이다.
도 6은 45 ℃에서 제조된 실시예 제제들의 과아세트산 함량을 숙성 시간에 따라 측정한 결과를 나타낸 것이다.
도 7은 기존 시판 제형과 F002, F006 및 F006-1 제형의 염 석출 시험 결과를 나타낸 것이다.Figure 1 shows the results of measuring the hydrogen peroxide content of example preparations prepared at room temperature according to aging time.
Figure 2 shows the results of measuring the peracetic acid content of example preparations prepared at room temperature according to aging time.
Figure 3 shows the results of measuring the hydrogen peroxide content of example preparations prepared at 35°C according to aging time.
Figure 4 shows the results of measuring the peracetic acid content of example preparations prepared at 35°C according to aging time.
Figure 5 shows the results of measuring the hydrogen peroxide content of example preparations prepared at 45°C according to aging time.
Figure 6 shows the results of measuring the peracetic acid content of example preparations prepared at 45°C according to aging time.
Figure 7 shows the salt precipitation test results of existing commercial formulations and F002, F006, and F006-1 formulations.
이하, 실시예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들 실시예에 의해 제한되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention and the scope of the present invention is not limited by these examples.
실시예: 과아세트산 제제의 제조방법Example: Method for producing peracetic acid preparation
실시예 1 (기존 당사 제형, F005)Example 1 (our existing formulation, F005)
아세트산무수물 31 ~ 43 % (w/w), 과산화수소수 35 % 액 33 ~ 39 % (w/w; 최종 함량 약 0.11 ~ 0.14 %)와 정제수를 넣어 혼합한 뒤, 안정화제로 1-히드록시에탄-1,1-디포스폰산을 넣어 혼합하였다. 3 시간 혼합 공정이 끝난 후, 경우에 따라 상온에서 숙성시킨 뒤 품질 시험을 진행하였다.Mix 31 to 43% (w/w) of acetic anhydride, 33 to 39% (w/w; final content approximately 0.11 to 0.14%) of hydrogen peroxide and purified water, then add 1-hydroxyethane- as a stabilizer. 1,1-diphosphonic acid was added and mixed. After the 3-hour mixing process was completed, in some cases, the product was aged at room temperature and then quality tested.
실시예 2 (F002, F003)Example 2 (F002, F003)
아세트산무수물 31 ~ 43 % (w/w), 과산화수소수 35 % 액 33 ~ 39 % (w/w)와 정제수를 넣어 혼합한 뒤, 안정화제로 1-히드록시에탄-1,1-디포스폰산을 넣어 혼합하고 pH를 조절하기 위해 인산을 1 ~ 3 %까지 투입하였다. 3 시간 혼합 공정이 끝난 후, 경우에 따라 상온에서 숙성시킨 뒤 품질 시험을 진행하였다.Mix 31 to 43% (w/w) of acetic anhydride, 33 to 39% (w/w) of 35% hydrogen peroxide and purified water, then add 1-hydroxyethane-1,1-diphosphonic acid as a stabilizer. It was mixed and phosphoric acid was added to 1 to 3% to adjust the pH. After the 3-hour mixing process was completed, in some cases, the product was aged at room temperature and then quality tested.
실시예 3 (F004, F006, F007, F008)Example 3 (F004, F006, F007, F008)
기존 과아세트산 제품들의 경우 대부분 인산을 함유하고 있었으나, 이 경우 수돗물 내 양이온과 반응하여 세척기 내 흰색의 염을 형성하는 문제점이 발생된다는 보고가 있었다. 따라서 실시예 3에서는 인산을 유사한 무기산의 한 종류인 붕산으로 변경하였다. 붕산의 경우 그 자체로 소독력과 방부력을 가지고 있으며, 인산에 비해 pH가 높아 상대적으로 부식력이 약한 물질로 알려져 있다.Most existing peracetic acid products contained phosphoric acid, but there were reports that this reacted with positive ions in tap water to form a white salt in the dishwasher. Therefore, in Example 3, phosphoric acid was changed to boric acid, a type of similar inorganic acid. In the case of boric acid, it has disinfecting and preservative properties, and is known to be a substance with relatively weak corrosive power due to its higher pH than phosphoric acid.
아세트산무수물 31 ~ 43 % (w/w), 과산화수소수 35 % 액 33 ~ 39 % (w/w)와 정제수를 넣어 혼합한 뒤, 안정화제로 1-히드록시에탄-1,1-디포스폰산을 넣어 혼합하고, pH를 조절하기 위해 붕산을 1 ~ 5 %까지 투입하였다. 3 시간 혼합 공정이 끝난 후, 경우에 따라 상온에서 숙성시킨 뒤 품질 시험을 진행하였다.Mix 31 to 43% (w/w) of acetic anhydride, 33 to 39% (w/w) of 35% hydrogen peroxide and purified water, then add 1-hydroxyethane-1,1-diphosphonic acid as a stabilizer. It was mixed, and boric acid was added to 1 to 5% to adjust the pH. After the 3-hour mixing process was completed, in some cases, the product was aged at room temperature and then quality tested.
실시예 4 (F006-1)Example 4 (F006-1)
실시예 4는 기존 F006에서 붕산 함량을 추가적으로 조정한 것이다. 아세트산무수물 41 % (w/w), 과산화수소수 35 % 액 33 % (w/w)와 정제수를 넣어 혼합한 뒤, 안정화제로 1-히드록시에탄-1,1-디포스폰산을 넣어 혼합하고 pH를 조절하기 위해 인산을 0.5 %로 투입하였다.Example 4 is a product in which the boric acid content was additionally adjusted in existing F006. Mix 41% (w/w) of acetic anhydride, 33% (w/w) of 35% hydrogen peroxide and purified water, then add 1-hydroxyethane-1,1-diphosphonic acid as a stabilizer, mix, and adjust pH. To control phosphoric acid was added at 0.5%.
실험예: 제조공정 별 비교실험Experimental example: Comparative experiment by manufacturing process
상기 실시예에 해당하는 각각의 과아세트산 제제 (기존 당사 제형 및 F002 내지 F008)를 상온 (20 ~ 25 ℃), 35 ℃ 또는 45 ℃에서 3 시간 반응시킨 뒤, 필요할 경우 상온에서 숙성시켰다. 그 다음, 적정법을 이용하여 과산화수소수 순도시험 및 과아세트산 함량 분석을 진행하였다. Each of the peracetic acid formulations corresponding to the above examples (our existing formulations and F002 to F008) were reacted at room temperature (20 to 25°C), 35°C or 45°C for 3 hours, and then aged at room temperature if necessary. Next, hydrogen peroxide purity test and peracetic acid content analysis were performed using titration method.
실험예 1. 과아세트산 6 %, 상온 공정Experimental Example 1. Peracetic acid 6%, room temperature process
[표 1][Table 1]
F : Fail, P : Pass, NT : Not testedF: Fail, P: Pass, NT: Not tested
과아세트산 제제에 있어서 과아세트산의 농도가 너무 낮으면 충분한 살균·소독 효과를 얻을 수 없고, 과산화수소 함량이 너무 높으면 인체에 해로운 영향을 주므로, 실시예로부터 제조된 제제들의 과산화수소 및 과아세트산 함량을 측정하고자 하였다. In peracetic acid preparations, if the concentration of peracetic acid is too low, sufficient sterilization and disinfection effects cannot be obtained, and if the hydrogen peroxide content is too high, it has a harmful effect on the human body. Therefore, to measure the hydrogen peroxide and peracetic acid contents of the preparations prepared in the examples. did.
먼저, 상온 공정 조건에서 과산화수소수의 순도 시험을 진행한 결과, 기존 당사 제형의 경우 약 10 일, F002는 7 일, F003, F004와 F005의 경우 4 일, F006은 2 일, F007과 F008은 1 일 경과 후 의약품 품질관리 기준에 적합함을 확인하였다 (표 1 및 도 1). First, as a result of conducting a purity test of hydrogen peroxide under room temperature process conditions, our existing formulation lasted about 10 days, F002 lasted 7 days, F003, F004 and F005 lasted 4 days, F006 lasted 2 days, and F007 and F008 lasted 1 day. After one day, it was confirmed that it complied with the pharmaceutical quality control standards (Table 1 and Figure 1).
순도시험 후 과아세트산 함량 시험 결과, 기존 당사 제형과 F002, F006는 6 % 함량 기준을 만족하기 위해 반응 후 추가적으로 4 일의 숙성시간이 필요하였으며, F007은 2 일, F008은 3 일의 숙성시간이 필요한 것으로 확인 되었다 (표 1 및 도 2). F003, F004, F005의 경우 순도 적합기한이 4 일 가량 필요하여, 과아세트산 함량 실험에서는 제외하였다.As a result of the peracetic acid content test after the purity test, our existing formulation, F002, and F006 required an additional 4 days of maturation time after reaction to meet the 6% content standard, while F007 required 2 days and F008 required 3 days of maturation time. It was confirmed to be necessary (Table 1 and Figure 2). In the case of F003, F004, and F005, the purity compliance period was about 4 days, so they were excluded from the peracetic acid content test.
실험예 2. 과아세트산 6 %, 35 ℃ 공정Experimental Example 2. Peracetic acid 6%, 35°C process
[표 2][Table 2]
35 ℃ 반응 조건에서, F008은 순도시험 품질기준을 만족시키기 위한 숙성시간이 최소 4 시간으로 단축되었으며, 과아세트산 6 % 함량 적합 기간은 3 시간으로 단축되었다 (표 2, 도 3 및 도 4). 즉, F008의 경우 과아세트산 합성에 추가적인 숙성은 요구되지 않았다. 상온 공정 보다 온도를 상승시켜 반응을 진행할 경우, 과아세트산 합성이 빠르게 됨을 확인 하였다.Under 35°C reaction conditions, the aging time for F008 to meet the purity test quality standards was shortened to at least 4 hours, and the compliance period for 6% peracetic acid content was shortened to 3 hours (Table 2, Figures 3 and 4). That is, in the case of F008, no additional maturation was required for peracetic acid synthesis. It was confirmed that peracetic acid synthesis becomes faster when the reaction is carried out at an elevated temperature compared to the room temperature process.
실험예 3. 과아세트산 6 %, 45 ℃ 공정Experimental Example 3. Peracetic acid 6%, 45°C process
[표 3][Table 3]
45 ℃ 반응 조건에서, F006은 순도시험 품질기준을 만족시키기 위해 추가 숙성이 요구되지 않았으며, F007 및 F008은 단 2 시간의 추가 숙성시간만이 필요했다 (표 3 및 도 5). F006 내지 F008 모두 반응 시간 3 시간만으로 과아세트산 6 % 함량 적합 기준을 만족하고 추가적인 숙성 기간이 필요하지 않음을 확인하였다 (표 3 및 도 6).At 45°C reaction conditions, F006 did not require additional aging to meet the purity test quality standards, and F007 and F008 required only 2 hours of additional aging time (Table 3 and Figure 5). It was confirmed that all F006 to F008 satisfied the peracetic acid 6% content standard with only 3 hours of reaction time and no additional aging period was required (Table 3 and Figure 6).
위 결과를 종합하면, 본 발명자들은 pH 조절제 첨가 시 첨가하지 않은 경우에 비해 과아세트산 합성 기간을 단축시킬 수 있음을 확인하였으며, 특히 인산을 첨가한 경우에 비해 붕산 첨가시 반응시간이 획기적으로 단축되는 것을 확인하였다. 또한, 상온에서 반응시킨 것과 비교하여 높은 온도에서 과아세트산 합성 기간 및 과산화수소 순도 적합 기간이 단축되는 것을 확인하였다. Summarizing the above results, the present inventors confirmed that the addition of a pH adjuster can shorten the peracetic acid synthesis period compared to the case without addition, and in particular, the reaction time is dramatically shortened when boric acid is added compared to the case of adding phosphoric acid. confirmed. In addition, it was confirmed that the peracetic acid synthesis period and hydrogen peroxide purity suitability period were shortened at high temperature compared to the reaction at room temperature.
실험예 4. 침전물 형성 검토Experimental Example 4. Examination of sediment formation
본 발명의 과초산 용액은 인산을 촉매로 사용하는 기존 제제와 달리, 과초산 합성을 빠르게 하기 위하여 촉매로 붕산을 사용하고 있다. 상기 실시예 1 내지 3에서는 붕산 사용 시 과초산 합성 시간이 단축되는 것을 확인하였는데, 다음으로 실시예 4에서는 인산을 촉매로 사용하는 기존 제제에서 문제점으로 지적되었던 염 침전 현상이 붕산 사용으로 개선될 수 있는지 여부를 확인하고자 하였다. Unlike existing preparations that use phosphoric acid as a catalyst, the peracetic acid solution of the present invention uses boric acid as a catalyst to speed up the synthesis of peracetic acid. In Examples 1 to 3, it was confirmed that the peracetic acid synthesis time was shortened when boric acid was used. Next, in Example 4, the salt precipitation phenomenon, which was pointed out as a problem in existing formulations using phosphoric acid as a catalyst, could be improved by using boric acid. I wanted to check whether it was there or not.
일반적으로 수돗물의 칼슘이온 농도는 약 5 ppm 수준으로 알려져 있는데, 촉매제로 인산이 포함된 소독액을 좋은 품질의 정제수, 역삼투압수 이외에 수돗물 등 기준 미달의 용매에 희석하여 사용하면 인산염 축적이 발생하고, 다회 사용되는 기존 소독액은 칼슘이온과 반응한 침전물이 형성/축적되어 소독기에 문제를 일으켰다. In general, the calcium ion concentration in tap water is known to be around 5 ppm. If a disinfectant solution containing phosphoric acid as a catalyst is diluted with a substandard solvent such as tap water in addition to good quality purified water or reverse osmosis water, phosphate accumulation occurs. Existing disinfectants used multiple times caused problems in the disinfector due to the formation/accumulation of precipitates that reacted with calcium ions.
붕산을 촉매로 사용한 본 발명의 제제의 염 형성을 평가하기 위해, 가혹조건으로 칼슘 이온을 약 10 배 수준 (55.49 ppm)으로 포함하는 물에 인산을 함유하는 기존 시판 제형 및 F002, 인산 대신 붕산을 함유하는 F006 및 F006-1을 각각 희석시키고 염이 형성되는 정도를 확인하였다. In order to evaluate the salt formation of the formulation of the present invention using boric acid as a catalyst, an existing commercial formulation containing phosphoric acid in water containing about 10 times the level of calcium ions (55.49 ppm) and F002, boric acid instead of phosphoric acid, were tested under severe conditions. Containing F006 and F006-1 were respectively diluted and the degree of salt formation was confirmed.
그 결과, 인산이 함유된 기존 시판 제형 및 F002에서는 칼슘염 침적물이 눈에 띄게 덩어리 형태로 형성되는 것을 확인할 수 있었다. 그러나, 붕산 촉매제를 포함하는 본 발명의 F006 및 F006-1 제제의 경우 기존 인산 함유 제제보다 칼슘염 형성이 눈에 띄게 억제되는 것을 확인할 수 있었다 (도 7). 이러한 결과는, 본 발명의 과아세트산 용액을 살균소독제로 사용할 경우 칼슘염 형성을 억제하고, 이에 따라 의료기기의 사용수명 연장 및 소독효과를 증대시킬 수 있음을 시사한다. As a result, it was confirmed that calcium salt deposits were noticeably formed in lumps in existing commercially available formulations containing phosphoric acid and F002. However, in the case of the F006 and F006-1 formulations of the present invention containing a boric acid catalyst, it was confirmed that calcium salt formation was noticeably suppressed compared to the existing phosphoric acid-containing formulations (FIG. 7). These results suggest that when the peracetic acid solution of the present invention is used as a sterilizing disinfectant, the formation of calcium salts can be suppressed, thereby extending the service life of medical devices and increasing the disinfection effect.
이상의 설명으로부터, 본 발명의 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without changing its technical idea or essential features. In this regard, the embodiments described above should be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed as including the meaning and scope of the patent claims described below rather than the detailed description above, and all changes or modified forms derived from the equivalent concept thereof are included in the scope of the present invention.
Claims (10)
(b) 상기 (a) 단계의 혼합물에 안정화제를 첨가하여 혼합하는 단계; 및
(c) 상기 (b) 단계의 혼합물에 붕산 0.5 중량% 내지 5 중량%를 혼합하고 30 ℃ 내지 50 ℃에서 2 시간 내지 4 시간 동안 반응시키는 단계를 포함하는, 단일제로 제공되는 과아세트산 용액의 제조방법.
(a) mixing 37% to 41% by weight of acetic anhydride, 10% to 12% by weight of hydrogen peroxide, and water;
(b) adding and mixing a stabilizer to the mixture of step (a); and
(c) Preparation of a peracetic acid solution provided as a single agent, comprising the step of mixing 0.5% by weight to 5% by weight of boric acid with the mixture of step (b) and reacting at 30 ℃ to 50 ℃ for 2 to 4 hours. method.
(d) 상기 (c) 단계의 반응물을 상온에서 숙성시키는 단계를 포함하는, 단일제로 제공되는 과아세트산 용액의 제조방법.
According to paragraph 1,
(d) A method for producing a peracetic acid solution provided as a single agent, comprising the step of maturing the reactant of step (c) at room temperature.
상기 숙성시키는 단계는 1 시간 내지 3 시간인, 단일제로 제공되는 과아세트산 용액의 제조방법.
According to paragraph 2,
The method of producing a peracetic acid solution provided as a single agent, wherein the aging step is 1 hour to 3 hours.
상기 (a) 단계의 아세트산 무수물은 39 중량%이고, 과산화수소수는 11.5 중량%이며,
상기 (c) 단계의 붕산은 2 중량%이고, 30 ℃ 내지 40 ℃에서 반응시키는 것인, 단일제로 제공되는 과아세트산 용액의 제조방법.
According to paragraph 1,
In step (a), acetic anhydride is 39% by weight, hydrogen peroxide is 11.5% by weight,
A method for producing a peracetic acid solution provided as a single agent, wherein the boric acid in step (c) is 2% by weight and the reaction is performed at 30 ℃ to 40 ℃.
상기 (a) 단계의 아세트산 무수물은 37 중량% 내지 41 중량%이고, 과산화수소수는 11.5 중량%이며,
상기 (c) 단계의 붕산은 2 중량%이고, 40 ℃ 내지 50 ℃에서 반응시키는 것인, 단일제로 제공되는 과아세트산 용액의 제조방법.
According to paragraph 1,
In step (a), acetic anhydride is 37% to 41% by weight, hydrogen peroxide is 11.5% by weight,
A method for producing a peracetic acid solution provided as a single agent, wherein the boric acid in step (c) is 2% by weight and the reaction is performed at 40°C to 50°C.
상기 (b) 단계의 안정화제는 1-히드록시에탄-1,1-디포스폰산, 1-옥탄설폰산나트륨, {[(카르복시메틸)이미노]비스(에틸렌니트릴로)}테트라아세트산 및 EDTA 소듐염으로 이루어진 군에서 선택된 어느 하나 이상인, 단일제로 제공되는 과아세트산 용액의 제조방법.
According to paragraph 1,
The stabilizers in step (b) include 1-hydroxyethane-1,1-diphosphonic acid, sodium 1-octanesulfonate, {[(carboxymethyl)imino]bis(ethylenenitrilo)}tetraacetic acid, and EDTA. A method for producing a peracetic acid solution provided as a single agent, which is at least one selected from the group consisting of sodium salts.
상기 안정화제는 0.1 중량% 내지 3 중량%인, 단일제로 제공되는 과아세트산 용액의 제조방법.
According to clause 6,
A method for producing a peracetic acid solution provided as a single agent, wherein the stabilizer is 0.1% to 3% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210142044A KR102610645B1 (en) | 2021-10-22 | 2021-10-22 | A rapid preparation method for a peracetic acid solution provided as single formulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210142044A KR102610645B1 (en) | 2021-10-22 | 2021-10-22 | A rapid preparation method for a peracetic acid solution provided as single formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230057824A KR20230057824A (en) | 2023-05-02 |
| KR102610645B1 true KR102610645B1 (en) | 2023-12-06 |
Family
ID=86387915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210142044A KR102610645B1 (en) | 2021-10-22 | 2021-10-22 | A rapid preparation method for a peracetic acid solution provided as single formulation |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102610645B1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100597092B1 (en) * | 2005-01-27 | 2006-07-04 | 이승훈 | Aqueous solution of peracetic acid and method for producing the same |
| US20100021558A1 (en) | 2008-07-24 | 2010-01-28 | Fmc Corporation | Dilute Aqueous Peracid Solutions and Stabilization Method |
| CN101781241A (en) | 2010-01-18 | 2010-07-21 | 江苏爱利思达清泉化学有限公司 | Preparation method of anhydrous peroxyacetic acid |
| CN102578144A (en) | 2011-01-13 | 2012-07-18 | 北京康福乐科技有限公司 | Product and method for generating peracetic acid |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000022931A1 (en) | 1998-10-19 | 2000-04-27 | Saraya Co., Ltd. | Bactericidal/disinfectant peracetic acid composition |
| KR100363896B1 (en) | 2000-04-21 | 2002-12-16 | 이진식 | A medical instrument cleaning solution using peracetic acid and the manufacturing method of the above solution |
| KR100876684B1 (en) | 2007-10-31 | 2009-01-07 | 이진식 | Preparation method of acidic antibiotic composition containing peracid and acetyl salicylic acid |
-
2021
- 2021-10-22 KR KR1020210142044A patent/KR102610645B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100597092B1 (en) * | 2005-01-27 | 2006-07-04 | 이승훈 | Aqueous solution of peracetic acid and method for producing the same |
| US20100021558A1 (en) | 2008-07-24 | 2010-01-28 | Fmc Corporation | Dilute Aqueous Peracid Solutions and Stabilization Method |
| CN101781241A (en) | 2010-01-18 | 2010-07-21 | 江苏爱利思达清泉化学有限公司 | Preparation method of anhydrous peroxyacetic acid |
| CN102578144A (en) | 2011-01-13 | 2012-07-18 | 北京康福乐科技有限公司 | Product and method for generating peracetic acid |
Non-Patent Citations (1)
| Title |
|---|
| Canadian Journal of Chemistry, Vol.41, 1963, pp.1826-1831* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230057824A (en) | 2023-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11653653B2 (en) | Stable compositions of uncomplexed iodine and methods of use | |
| JP7265871B2 (en) | Method for producing aqueous solution containing chlorous acid for use as disinfectant | |
| JP2843442B2 (en) | Compositions and methods of using them | |
| KR100597092B1 (en) | Aqueous solution of peracetic acid and method for producing the same | |
| CN104206413B (en) | A kind of thimerosal for haemodialysis control unit cleaning and sterilizing and preparation method thereof | |
| JP2014515737A (en) | Stable composition of HOCl, process for its production and use thereof | |
| CN108566954A (en) | A kind of disinfectant and its preparation method and application | |
| CN112088898B (en) | Composition containing oxidation-reduction potential water and preparation method thereof | |
| KR100876684B1 (en) | Preparation method of acidic antibiotic composition containing peracid and acetyl salicylic acid | |
| WO2004089089A1 (en) | Composition for bactericide production and process for producing organic peracid | |
| SI9520017A (en) | Microbicidal preparation with low toxicity level, containimng a quaternary ammonia | |
| KR102610645B1 (en) | A rapid preparation method for a peracetic acid solution provided as single formulation | |
| JP2002249407A (en) | Sterilizing disinfectant | |
| KR20080098157A (en) | Sterilant.disinfectant composition comprising peracetic acid | |
| KR102127417B1 (en) | Compositions for sterilization and disinfection using hydrogen peroxide | |
| JP2011502143A (en) | Bactericidal composition comprising peracid and acetylsalicylic acid | |
| US20220323488A1 (en) | Preparations for controlled-release of hypochlorous acid | |
| KR102307392B1 (en) | Peracetic acid disinfectant composition for medical devices with improved stability | |
| KR102353182B1 (en) | Percitric acid aqueous solution and method for producing the same | |
| EP0255875A1 (en) | Glutaraldehyde-based sterilising composition of antibacterial and antimycotic activity in an aqueous vehicle | |
| CN107372597A (en) | A kind of Hydrogen Peroxide Disinfectant and preparation method thereof | |
| CN108272649B (en) | IgY-containing clear mouthwash and preparation method thereof | |
| US5116623A (en) | Periodate iodophor composition with increased stability | |
| CA2164308C (en) | Sodium hypochlorite based disinfectant and sterilizer for medical-surgical instruments | |
| JP2003034605A (en) | Composition for sterilization and disinfection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |